Oncology Central

NHS England strikes deal for ground-breaking CAR-T therapy in a new European first

Adult cancer patients in England will receive the game-changing CAR-T therapy Yescarta® (axicabtagene ciloleucel), under the first negotiated deal of its kind struck in Europe.

This is the first time adult patients will have access to CAR-T via the National Health Service (NHS), and follows a deal NHS England reached last month to make Kymriah® available for children and young people with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.